Please enable JavaScript to continue using this application.

Compare $CGON vs $IMVT | Chartloom

Compare

$CGON vs $IMVT

CG Oncology Inc · Immunovant Inc

CGON

CG Oncology Inc

IMVT

Immunovant Inc

Compare $CGON vs $IMVT

Comparing CG Oncology Inc and Immunovant Inc

CGONCG Oncology Inc

IMVTImmunovant Inc

CGONCG Oncology Inc

Market cap

$5.63B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

135.78x

Rev growth (TTM)

1030.3%

YTD performance

52.7%

52W performance

56.8%

FCF yield

-3.2%

IMVTImmunovant Inc

Market cap

$6.29B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

17.6%

52W performance

89.5%

FCF yield

-6.6%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CGON

IMVT

Detailed metrics comparison

CGON

CG Oncology Inc

IMVT

Immunovant Inc

Market Cap

CGON$5.63B

IMVT$6.29B

Enterprise Value

CGON$5.61B

IMVT$5.49B

Price

CGON$63.82

IMVT$30.47

P/E Ratio

CGONN/A

IMVTN/A

P/S Ratio

CGON903.81x

IMVT0.00x

EV/Sales

CGON901.14x

IMVT0.00x

EV/EBITDA

CGON0.00x

IMVT0.00x

P/B Ratio

CGON5.80x

IMVT9.44x

P/FCF Ratio

CGONN/A

IMVTN/A

EV/FCF

CGON-31.29x

IMVT-13.25x

PEG Ratio

CGONN/A

IMVTN/A

Forward P/E (NTM)

CGONN/A

IMVTN/A

Forward P/S (NTM)

CGON135.78x

IMVTN/A

Revenue (TTM)

CGON$6M

IMVT$0

Revenue Growth (YoY)

CGON1030.3%

IMVTN/A

Forward Rev Growth

CGON1916.0%

IMVT546.2%

Gross Margin (TTM)

CGON-85.2%

IMVT0.0%

Operating Margin (TTM)

CGON0.0%

IMVT0.0%

EBITDA Margin (TTM)

CGON-4008.7%

IMVT0.0%

Net Margin (TTM)

CGON-3602.7%

IMVT0.0%

FCF Margin (TTM)

CGON-2879.6%

IMVTN/A

Net Income (TTM)

CGON$-224M

IMVT$-538M

FCF (TTM)

CGON$-179M

IMVT$-414M

EPS (TTM)

CGON-$2.54

IMVT-$2.62

ROE (TTM)

CGON-2520.0%

IMVT-6959.0%

ROA (TTM)

CGON-2398.0%

IMVT-6250.0%

ROIC (TTM)

CGON-2512.0%

IMVT-6959.0%

Cash

CGON$20M

IMVT$798M

Debt

CGON$3M

IMVT$0

Net Cash/Debt

CGON$17M

IMVT$798M

Current Ratio (TTM)

CGON22.22x

IMVT7.27x

Quick Ratio (TTM)

CGON21.78x

IMVT6.82x

Debt/Equity (TTM)

CGON0.00x

IMVT0.00x

Debt/Assets (TTM)

CGON0.0%

IMVT0.0%

Interest Coverage (TTM)

CGONN/A

IMVTN/A

Net Debt/EBITDA (TTM)

CGON0.00x

IMVT0.00x

Beta

CGON0.25

IMVT0.92

52W Performance

CGON56.8%

IMVT89.5%

YTD Performance

CGON52.7%

IMVT17.6%

% from 52W High

CGON-21.2%

IMVT-32.9%

% from 52W Low

CGON78.3%

IMVT89.5%

Asset Turnover (TTM)

CGON0.01x

IMVT0.00x

FCF Yield (TTM)

CGON-3.2%

IMVT-6.6%

Earnings Yield (TTM)

CGON-4.0%

IMVT-8.6%

Dividend Yield (TTM)

CGONN/A

IMVTN/A

Rule of 40

CGON-1,849.3

IMVT0.0

EV/GP/RG

CGONN/A

IMVTN/A

Ticker research

View CGON research View IMVT research

Metric	CGON CG Oncology Inc	IMVT Immunovant Inc
Market & Valuation
Market Cap	$5.63B	$6.29B
Enterprise Value	$5.61B	$5.49B
Price	$63.82	$30.47
P/E Ratio	N/A	N/A
P/S Ratio	903.81x	0.00x
EV/Sales	901.14x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	5.80x	9.44x
P/FCF Ratio	N/A	N/A
EV/FCF	-31.29x	-13.25x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	135.78x	N/A
Revenue & Growth
Revenue (TTM)	$6M	$0
Revenue Growth (YoY)	1030.3%	N/A
Forward Rev Growth	1916.0%	546.2%
Profitability
Gross Margin (TTM)	-85.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-4008.7%	0.0%
Net Margin (TTM)	-3602.7%	0.0%
FCF Margin (TTM)	-2879.6%	N/A
Net Income (TTM)	$-224M	$-538M
FCF (TTM)	$-179M	$-414M
EPS (TTM)	-$2.54	-$2.62
ROE (TTM)	-2520.0%	-6959.0%
ROA (TTM)	-2398.0%	-6250.0%
ROIC (TTM)	-2512.0%	-6959.0%
Financial Health
Cash	$20M	$798M
Debt	$3M	$0
Net Cash/Debt	$17M	$798M
Current Ratio (TTM)	22.22x	7.27x
Quick Ratio (TTM)	21.78x	6.82x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.25	0.92
52W Performance	56.8%	89.5%
YTD Performance	52.7%	17.6%
% from 52W High	-21.2%	-32.9%
% from 52W Low	78.3%	89.5%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-3.2%	-6.6%
Earnings Yield (TTM)	-4.0%	-8.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,849.3	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CGON research	View IMVT research

Valuation

P/S Ratio

IMVT

0.00x

CGON

903.81x

EV/FCF

CGON

-31.29x

IMVT

-13.25x

Growth & revenue

Revenue Growth TTM

CGON

1030.3%

Forward Revenue Growth

CGON

1916.0%

IMVT

546.2%

Profitability & performance

Gross Margin

IMVT

0.0%

CGON

-85.2%

ROE

CGON

-2520.0%

IMVT

-6959.0%

FCF Yield %

CGON

-3.2%

IMVT

-6.6%

52-Week Performance

IMVT

89.5%

CGON

56.8%

Detailed metrics comparison

CGON

CG Oncology Inc

IMVT

Immunovant Inc

Market Cap

CGON$5.63B

IMVT$6.29B

Enterprise Value

CGON$5.61B

IMVT$5.49B

Price

CGON$63.82

IMVT$30.47

P/E Ratio

CGONN/A

IMVTN/A

P/S Ratio

CGON903.81x

IMVT0.00x

EV/Sales

CGON901.14x

IMVT0.00x

EV/EBITDA

CGON0.00x

IMVT0.00x

P/B Ratio

CGON5.80x

IMVT9.44x

P/FCF Ratio

CGONN/A

IMVTN/A

EV/FCF

CGON-31.29x

IMVT-13.25x

PEG Ratio

CGONN/A

IMVTN/A

Forward P/E (NTM)

CGONN/A

IMVTN/A

Forward P/S (NTM)

CGON135.78x

IMVTN/A

Revenue (TTM)

CGON$6M

IMVT$0

Revenue Growth (YoY)

CGON1030.3%

IMVTN/A

Forward Rev Growth

CGON1916.0%

IMVT546.2%

Gross Margin (TTM)

CGON-85.2%

IMVT0.0%

Operating Margin (TTM)

CGON0.0%

IMVT0.0%

EBITDA Margin (TTM)

CGON-4008.7%

IMVT0.0%

Net Margin (TTM)

CGON-3602.7%

IMVT0.0%

FCF Margin (TTM)

CGON-2879.6%

IMVTN/A

Net Income (TTM)

CGON$-224M

IMVT$-538M

FCF (TTM)

CGON$-179M

IMVT$-414M

EPS (TTM)

CGON-$2.54

IMVT-$2.62

ROE (TTM)

CGON-2520.0%

IMVT-6959.0%

ROA (TTM)

CGON-2398.0%

IMVT-6250.0%

ROIC (TTM)

CGON-2512.0%

IMVT-6959.0%

Cash

CGON$20M

IMVT$798M

Debt

CGON$3M

IMVT$0

Net Cash/Debt

CGON$17M

IMVT$798M

Current Ratio (TTM)

CGON22.22x

IMVT7.27x

Quick Ratio (TTM)

CGON21.78x

IMVT6.82x

Debt/Equity (TTM)

CGON0.00x

IMVT0.00x

Debt/Assets (TTM)

CGON0.0%

IMVT0.0%

Interest Coverage (TTM)

CGONN/A

IMVTN/A

Net Debt/EBITDA (TTM)

CGON0.00x

IMVT0.00x

Beta

CGON0.25

IMVT0.92

52W Performance

CGON56.8%

IMVT89.5%

YTD Performance

CGON52.7%

IMVT17.6%

% from 52W High

CGON-21.2%

IMVT-32.9%

% from 52W Low

CGON78.3%

IMVT89.5%

Asset Turnover (TTM)

CGON0.01x

IMVT0.00x

FCF Yield (TTM)

CGON-3.2%

IMVT-6.6%

Earnings Yield (TTM)

CGON-4.0%

IMVT-8.6%

Dividend Yield (TTM)

CGONN/A

IMVTN/A

Rule of 40

CGON-1,849.3

IMVT0.0

EV/GP/RG

CGONN/A

IMVTN/A

Ticker research

View CGON research View IMVT research

Metric	CGON CG Oncology Inc	IMVT Immunovant Inc
Market & Valuation
Market Cap	$5.63B	$6.29B
Enterprise Value	$5.61B	$5.49B
Price	$63.82	$30.47
P/E Ratio	N/A	N/A
P/S Ratio	903.81x	0.00x
EV/Sales	901.14x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	5.80x	9.44x
P/FCF Ratio	N/A	N/A
EV/FCF	-31.29x	-13.25x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	135.78x	N/A
Revenue & Growth
Revenue (TTM)	$6M	$0
Revenue Growth (YoY)	1030.3%	N/A
Forward Rev Growth	1916.0%	546.2%
Profitability
Gross Margin (TTM)	-85.2%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-4008.7%	0.0%
Net Margin (TTM)	-3602.7%	0.0%
FCF Margin (TTM)	-2879.6%	N/A
Net Income (TTM)	$-224M	$-538M
FCF (TTM)	$-179M	$-414M
EPS (TTM)	-$2.54	-$2.62
ROE (TTM)	-2520.0%	-6959.0%
ROA (TTM)	-2398.0%	-6250.0%
ROIC (TTM)	-2512.0%	-6959.0%
Financial Health
Cash	$20M	$798M
Debt	$3M	$0
Net Cash/Debt	$17M	$798M
Current Ratio (TTM)	22.22x	7.27x
Quick Ratio (TTM)	21.78x	6.82x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.25	0.92
52W Performance	56.8%	89.5%
YTD Performance	52.7%	17.6%
% from 52W High	-21.2%	-32.9%
% from 52W Low	78.3%	89.5%
Efficiency & Yields
Asset Turnover (TTM)	0.01x	0.00x
FCF Yield (TTM)	-3.2%	-6.6%
Earnings Yield (TTM)	-4.0%	-8.6%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-1,849.3	0.0
EV/GP/RG	N/A	N/A
Ticker research	View CGON research	View IMVT research